CIMIT’s Inhalation Technology Program (ITP) explores using the respiratory tract to diagnose and treat both acute and chronic respiratory and non-respiratory ailments. Respiratory diseases, from infections to obstructive lung disease to cancer, are major public health problems, and acute respiratory infections are the third largest cause of death worldwide. This CIMIT program seeks to develop technologies to facilitate inhalation therapy that will help reduce human suffering and eventually health care costs.
Three priorities differentiate the CIMIT Inhalation Technology Program from all others:
Progress has been made on each of these aims. Three top researchers lead this program, Augustine Choi, MD, of Brigham and Women’s Hospital, Jose Venegas, PhD, of Massachusetts General Hospital, and Jussi Saukkonen, MD, of Boston Medical Center and the West Roxbury Veterans Administration Medical Center. Several luminaries in the field have joined the Inhalation Technology Advisory Council and several potential industry partners and research organizations are actively participating in the program consortium.
In the program’s first year, three Inhalation Technology projects were awarded funding and facilitation grants by CIMIT. Two Clinical Investigators working in the field of Inhalation Technology received the CIMIT Young Clinician Award, and one Medical Research grant through Department of Defense was awarded.
Five educational CIMIT forums were dedicated to Inhalation Technology in 2009. Summaries and videos of Forum and 2009 Summer Education Series are available online. Research results are published in peer review journals and presented at national meetings.
The ITP’s future work plan seeks to move forward on all three aims. To advance the program’s leading-edge vision, CIMIT is finalizing a high-level Scientific Advisory Council and establishing an Inhalation Technology Consortium by recruiting investigators, companies, organizations into the program. To facilitate research, the team will establish CIMIT core research tools or resource centers, enthusiastically support its research project award recipients, actively seek other grant and funding opportunities to support ITP research priorities and explore international collaborative opportunities.
The ITP advances its educational mission through Focus Sessions at the CIMIT Innovation Congress, new convening opportunities through webcasting of the CIMIT Forum, and the three-day Harvard Lung Conference and CIMIT Inhalation Technology Workshop scheduled for fall, 2010. All events showcase ITP research and novel technologies for diagnosis and treatment of lung diseases.
Significant progress is being made in establishing the CIMIT Inhalational Technology Program as the world-leading resource in research and treatment of serious respiratory conditions.
• 300 million worldwide suffer from asthma
• 250,000 annual deaths are attributed to the disease
• 100 million more people are estimated to have asthma by 2025
Airway obstruction in asthma is usually reversible, however if left untreated it can result in lung inflammation and irreversible obstruction.
Pulmonary Artery Hypertension (PH) is the increase of pressure in pulmonary arteries. The walls of these arteries tighten, forcing the heart to work harder to carry blood to the lungs for oxygen. This raises blood pressure and weakens the heart.
• Most common in older women
• Tends to limit all physical activity
Currently there is no cure for PH, however early treatment makes the disease easier to control.
Chronic Obstructive Pulmonary Disease (COPD), also known as emphysema or chronic bronchitis, is a progressive lung disease that makes it hard to breathe and causes long-term disability.
• 4th leading cause of death in US
• Over 12 million are currently diagnosed
• An additional 12 million are likely to have COPD and not realize it
COPD has no cure yet, however treatments and changes to lifestyle can help slow the progression of the disease and allow improve quality of active life.